NCT04769050UNKNOWNanonymous

A Phase II, Single-center, Dynamic Observational Study With PET of 68Ga-HER2-affibody in Anti-HER2 Treatment

Sponsor

Source record

Fudan University

Phase

Source record

Not classified

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Docetaxel combined with Trastuzumab±Pertuzumab, T-DM1 or Capecitabine combined with Pyrotinib regimen.

Indication / condition

AI-normalized

Breast Cancer

Intervention

Source record

Docetaxel combined with Trastuzumab±Pertuzumab, T-DM1 or Capecitabine combined with Pyrotinib regimen.

Source & freshness

Source record

NCT ID

NCT04769050

Original source

ClinicalTrials.gov

Source last updated

Apr 20, 2022

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT04769050

Title

A Phase II, Single-center, Dynamic Observational Study With PET of 68Ga-HER2-affibody in Anti-HER2 Treatment

Sponsor

Fudan University

Status

UNKNOWN

Phase

Detailed source ingestion pending

Condition raw

Breast Cancer

Condition normalized

Breast Cancer

Modality raw

Breast Cancer

Modality normalized

monoclonal antibody

Target raw

Docetaxel combined with Trastuzumab±Pertuzumab, T-DM1 or Capecitabine combined with Pyrotinib regimen.

Target normalized

Docetaxel combined with Trastuzumab±Pertuzumab, T-DM1 or Capecitabine combined with Pyrotinib regimen.

Interventions

Docetaxel combined with Trastuzumab±Pertuzumab, T-DM1 or Capecitabine combined with Pyrotinib regimen.

Public preview

Source record

Dynamic observationaL study with PET of 68Ga-HER2-affibody in anti-HER2 treatment

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase II, Single-center, Dynamic Observational Study With PET of 68Ga-HER2-affibody in Anti-HER2 Treatment

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT04769050

Status

UNKNOWN

Phase

N/A

Sponsor

Fudan University

Executive brief

Investment-Ready Snapshot

Dynamic observationaL study with PET of 68Ga-HER2-affibody in anti-HER2 treatment

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedApr 20, 2022

Internal syncJun 05, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT04769050

Indication

Breast Cancer

Modality

monoclonal antibody

Target

Docetaxel combined with Trastuzumab±Pertuzumab, T-DM1 or Capecitabine combined with Pyrotinib regimen.

Intervention

Docetaxel combined with Trastuzumab±Pertuzumab, T-DM1 or Capecitabine combined with Pyrotinib regimen.

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.